Oruka Therapeutics, Inc. Fair Value, Assets, Level 1 to Level 2 Transfers, Amount
Oruka Therapeutics, Inc. (ORKA) had Fair Value, Assets, Level 1 to Level 2 Transfers, Amount of $0 as of 2012-12-31, per its 10-K filed 2013-03-21.
Discontinued › Notes › Fair Value Measures and Disclosures
us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount · last filed 2013-03-21
- 2012-12-31: Fair Value, Assets, Level 1 to Level 2 Transfers, Amount $0.00.
- 2011-12-31: Fair Value, Assets, Level 1 to Level 2 Transfers, Amount $0.00.
| Period end | Fair Value, Assets, Level 1 to Level 2 Transfers, Amount |
|---|---|
| 2012-12-31 | $0.00 10-K · filed 2013-03-21 |
| 2011-12-31 | $0.00 10-K · filed 2013-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Veradermics, Inc (MANE) | United States | $4.839B |